Search

Your search keyword '"Rouleau, J"' showing total 734 results

Search Constraints

Start Over You searched for: Author "Rouleau, J" Remove constraint Author: "Rouleau, J"
734 results on '"Rouleau, J"'

Search Results

1. Echocardiographic characterization of patients with supranormal ejection fraction: pooled core laboratory analysis of the TOPCAT and PARAGON-HF trials

2. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

3. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial

5. THE RECARDIO TRIAL PROTOCOL: COMPARING THE EFFECTS OF COGNITIVE TRAINING AND PHYSICAL EXERCISE ON COGNITION AND CEREBRAL AUTOREGULATION IN MEN AND WOMEN WITH HEART FAILURE

12. Angiotensin–neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure

13. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial

15. History of stroke in patients with heart failure: prevalence, baseline characteristics and clinical outcomes

16. Prognostic importance of NT-proBNP following high-risk myocardial infarction in the PARADISE-MI Trial

18. Stroke in patients with heart failure and reduced ejection fraction without atrial fibrillation: external validation of a risk model

19. Alkaline phosphatase and bilirubin combined are a powerful predictor of outcome in patients with heart failure and reduced ejection fraction: an analysis of the ATMOSPHERE and PARADIGM-HF trials

20. Sacubitril/valsartan compared to ramipril in high risk post myocardial infarction patients stratified according use of mineralocorticoid receptor antagonists: insight from PARADISE MI trial

21. PARADISE-MI – event rates and treatment effect of sacubitril/valsartan v ramipril by the presence or absence of transient pulmonary congestion and/or LVEF less or greater than 40

22. A comprehensive study of the incremental prognostic value of novel biomarkers in PARADIGM-HF (Bio-PREDICT-HF)

23. Implications of the 2021 CKD-EPI cystatin C/creatinine eGFR equation for eligibility for therapy in HFrEF: insights from PARADIGM-HF

25. Aptamer proteomics for biomarker discovery in heart failure with reduced ejection fraction

26. Angiotensin receptor–neprilysin inhibition in acute myocardial infarction

27. Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial

28. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights from a Combined PARAGON-HF and PARADIGM-HF Analysis

30. Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial

31. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

32. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

35. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction

36. Abstracts of original contributions ASNC 2004 9th annual scientific session September 3-–October 3, 2004 New York, New York

41. Effect of Nesiritide in Patients with Acute Decompensated Heart Failure

42. OPTIMIZATION OF EVIDENCE-BASED THERAPIES FOR HEART FAILURE AND REDUCED EJECTION FRACTION PATIENTS IMPROVES OUTCOMES IN AN AMBULATORY SPECIALIZED SETTING

44. The continuous heart failure spectrum: Moving beyond an ejection fraction classification

45. Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

48. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

Catalog

Books, media, physical & digital resources